Literature DB >> 1427819

The CCAAT/enhancer binding protein (C/EBP alpha) gene (CEBPA) maps to human chromosome 19q13.1 and the related nuclear factor NF-IL6 (C/EBP beta) gene (CEBPB) maps to human chromosome 20q13.1.

L R Hendricks-Taylor1, L L Bachinski, M J Siciliano, A Fertitta, B Trask, P J de Jong, D H Ledbetter, G J Darlington.   

Abstract

The CEBPA gene encoding CCAAT/enhancer binding protein (C/EBP alpha) has been mapped to human chromosome 19 and the CEBPB (formerly TCF5) gene encoding NF-IL6 (C/EBP beta) to human chromosome 20 by Southern blot analysis of Chinese hamster x human and mouse x human somatic cell hybrids. CEBPA has been further mapped to 19q13.1 between the loci GPI and TGFB using human x hamster somatic cell hybrids containing restricted fragments of human chromosome 19. This position was confirmed by fluorescence in situ hybridization. Furthermore, CEBPB has been mapped to 20q13.1 by fluorescence in situ hybridization.

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1427819     DOI： 10.1016/s0888-7543(05)80276-9

Source DB:  PubMed          Journal:  Genomics        ISSN： 0888-7543            Impact factor:   5.736


  10 in total

Review 1.  CCAAT/enhancer-binding proteins and the pathogenesis of retrovirus infection.

Authors:  Yujie Liu; Michael R Nonnemacher; Brian Wigdahl
Journal:  Future Microbiol       Date:  2009-04       Impact factor: 3.165

2.  Location of the DBP transcription factor gene in human and mouse.

Authors:  L Stubbs; E Carver; L Ashworth; L Lopez-Molina
Journal:  Mamm Genome       Date:  1996-01       Impact factor: 2.957

3.  An informative panel of somatic cell hybrids for physical mapping on human chromosome 19q.

Authors:  L L Bachinski; R Krahe; B F White; B Wieringa; D Shaw; R Korneluk; L H Thompson; K Johnson; M J Siciliano
Journal:  Am J Hum Genet       Date:  1993-02       Impact factor: 11.025

4.  Identification of LZTFL1 as a candidate effector gene at a COVID-19 risk locus.

Authors:  Amy R Cross; Peng Hua; Damien J Downes; Nigel Roberts; Ron Schwessinger; Antony J Cutler; Altar M Munis; Jill Brown; Olga Mielczarek; Carlos E de Andrea; Ignacio Melero; Deborah R Gill; Stephen C Hyde; Julian C Knight; John A Todd; Stephen N Sansom; Fadi Issa; James O J Davies; Jim R Hughes
Journal:  Nat Genet       Date:  2021-11-04       Impact factor: 38.330

Review 5.  The role of C/EBPbeta in mammary gland development and breast cancer.

Authors:  Sandra L Grimm; Jeffrey M Rosen
Journal:  J Mammary Gland Biol Neoplasia       Date:  2003-04       Impact factor: 2.673

6.  Gene organization and primary structure of human hormone-sensitive lipase: possible significance of a sequence homology with a lipase of Moraxella TA144, an antarctic bacterium.

Authors:  D Langin; H Laurell; L S Holst; P Belfrage; C Holm
Journal:  Proc Natl Acad Sci U S A       Date:  1993-06-01       Impact factor: 11.205

7.  Autoregulation of the human C/EBP alpha gene by stimulation of upstream stimulatory factor binding.

Authors:  N Timchenko; D R Wilson; L R Taylor; S Abdelsayed; M Wilde; M Sawadogo; G J Darlington
Journal:  Mol Cell Biol       Date:  1995-03       Impact factor: 4.272

Review 8.  Development of MTL-CEBPA: Small Activating RNA Drug for Hepatocellular Carcinoma.

Authors:  Ryan L Setten; Helen L Lightfoot; Nagy A Habib; John J Rossi
Journal:  Curr Pharm Biotechnol       Date:  2018       Impact factor: 2.837

9.  PGC1α/CEBPB/CPT1A axis promotes radiation resistance of nasopharyngeal carcinoma through activating fatty acid oxidation.

Authors:  Qianqian Du; Zheqiong Tan; Feng Shi; Min Tang; Longlong Xie; Lin Zhao; Yueshuo Li; Jianmin Hu; Min Zhou; Ann Bode; Xiangjian Luo; Ya Cao
Journal:  Cancer Sci       Date:  2019-05-03       Impact factor: 6.716

10.  Programming With Varying Dietary Fat Content Alters Cardiac Insulin Receptor, Glut4 and FoxO1 Immunoreactivity in Neonatal Rats, Whereas High Fat Programming Alters Cebpa Gene Expression in Neonatal Female Rats.

Authors:  Annelene Govindsamy; Samira Ghoor; Marlon E Cerf
Journal:  Front Endocrinol (Lausanne)       Date:  2022-01-05       Impact factor: 5.555
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.